Reduced muscle mass and accumulation of visceral fat are independently associated with increased arterial stiffness in postmenopausal women with type 2 diabetes mellitus (T2DM). Reduced muscle mass and increased visceral fat are independently associated with increased arterial stiffness in postmenopausal women with T2DM. Diabetes Research and Clinical Practice, 11/05/2016. (Also see Causes of Diabetes)
Omics studies: their use in diagnosis and reclassification of systemic lupus erythematosus (SLE) and other systemic autoimmune diseases (SADs). This review summarizes the omics findings for SLE and propose ways of using the data for the identification of new biomarkers, finding new drugs and reclassifying patients not only with SLE, but also with other SADs. Rheumatology, 10/19/2016. (Also see Diagnosis of Lupus)
The diagnosis and management of the haematologic manifestations of lupus (SLE). In this review the most common and characteristic haematological manifestations of SLE patients are considered, focusing on their pathogenesis and management. PubMed, J Autoimmun, 2016 Nov;74:139-160. (Also see Diagnosis of Lupus)
Evaluation of a patient decision aid (PtDA) for initiating disease modifying anti–rheumatic drugs. The PtDA can be a valuable aid in improving patient participation in decision–making about disease modifying anti–rheumatic drugs (DMARDs). BioMed Central, Arthritis Research & Therapy, 10/28/2016. (Also see DMARDs)
Are foot and ankle characteristics associated with falls in people with rheumatoid arthritis (RA)? A prospective study. Foot and ankle characteristics are not associated with falls in people with RA and enquiries about prior falls and psychotropic medications may assist in identifying patients with RA who are at high risk of future falls. PubMed, Arthritis Care Res (Hoboken), 10/21/2016. (Also see Symptoms and Complications of Rheumatoid Arthritis)
Phenome–wide association study (PheWAS) of autoantibodies to citrullinated and non–citrullinated epitopes in rheumatoid arthritis (RA). PheWAS identified potential significant links between variations in levels of autoantibodies and comorbidities of interest in RA. PubMed, Arthritis Rheumatol, 10/28/2016. (Also see Causes of Rheumatoid Arthritis)
The development of psoriatic arthritis (PsA) in patients with psoriasis is preceded by a period of non–specific musculoskeletal symptoms: A prospective cohort study. A preclinical phase exists in patients with PsA prior to the diagnosis of the disease and is characterized by non–-specific musculoskeletal symptoms including joint pain, fatigue and stiffness. PubMed, Arthritis Rheumatol, 10/28/2016. (Also see Psoriasis and Psoriatic Arthritis)
Psoriatic arthritis (PsA) is associated with bone loss of the metacarpals. The BoneXpert (BX) MCI score showed periarticular demineralisation and severity–dependent bone loss in patients with PsA. PubMed, Arthritis Res Ther, 2016 Oct 25;18(1):248. (Also see Psoriasis and Psoriatic Arthritis)
Increased circulating anti–α6–integrin autoantibodies in psoriasis (Ps) and psoriatic arthritis (PsA) but not in rheumatoid arthritis (RA). This study shows the presence of anti–α6–integrin antibodies in Ps and PsA but not in RA, which could indicate ongoing abnormal processes in the skin. PubMed, J Dermatol, 10/28/2016. (Also see Psoriasis and Psoriatic Arthritis and Causes of Rheumatoid Arthritis)
Risk of high–grade cervical dysplasia and cervical cancer in women with systemic lupus erythematosus (SLE) receiving immunosuppressive drugs. Among women with SLE, immunosuppressive drugs may be associated with a greater, albeit not statistically significant, risk of high–grade cervical dysplasia and cervical cancer compared to patients receiving hydroxychloroquine alone. PubMed, Lupus, 10/31/2016. (Also see Immunosuppressants, Treatments for Lupus and Cancer)
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Juliet Youkhana; and donations in loving memory of Jim Miller and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE sclero.org button.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: